Werewolf Therapeutics (NASDAQ:HOWL) Rating Reiterated by HC Wainwright

Posted by on Nov 2nd, 2023

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $15.00 price objective on the stock.

Separately, Wedbush began coverage on shares of Werewolf Therapeutics in a research report on Wednesday, August 23rd. They set an “outperform” rating and a $9.00 price target for the company.

Get Our Latest Stock Report on Werewolf Therapeutics

Werewolf Therapeutics Trading Down 8.8 %

Shares of HOWL opened at $2.28 on Tuesday. The stock has a market capitalization of $81.30 million, a P/E ratio of -1.80 and a beta of 0.25. The company has a quick ratio of 9.82, a current ratio of 9.82 and a debt-to-equity ratio of 0.33. The firm has a fifty day simple moving average of $2.37 and a two-hundred day simple moving average of $2.71. Werewolf Therapeutics has a twelve month low of $1.39 and a twelve month high of $4.57.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.27. The business had revenue of $8.08 million during the quarter, compared to analysts’ expectations of $3.05 million. Werewolf Therapeutics had a negative net margin of 165.15% and a negative return on equity of 33.23%. On average, research analysts anticipate that Werewolf Therapeutics will post -1.16 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in HOWL. Jane Street Group LLC bought a new position in Werewolf Therapeutics in the 4th quarter worth $45,000. Bailard Inc. bought a new position in shares of Werewolf Therapeutics in the 1st quarter worth about $47,000. Cubist Systematic Strategies LLC bought a new position in shares of Werewolf Therapeutics in the 2nd quarter worth about $54,000. Two Sigma Investments LP bought a new position in shares of Werewolf Therapeutics in the 4th quarter worth about $56,000. Finally, Renaissance Technologies LLC bought a new position in shares of Werewolf Therapeutics in the 2nd quarter worth about $69,000. 67.44% of the stock is currently owned by institutional investors.

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.

Featured Stories

Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.